PROJECT PUBLICATIONS

WP2: Development and application of a tool to combine and use RCT and observational/registry data in economic evaluation





WP3: Developing a costing methodology and a database of unit costs


  • Špacírová Z, Epstein D, García-Mochón L et al. (2020) A general framework for classifying costing methods for economic evaluation of health care. European Journal of Health Economics 21, 529–542 [https://doi.org/10.1007/s10198-019-01157-9]
  • Adjusting costs for inflation in economic evaluations of healthcare – Poster [PDF]
  • García-Mochón L, Špacírová Z, Espín J (2021) Costing methodologies in European economic evaluation guidelines: commonalities and divergences. European Journal of Health Economics. doi: 10.1007/s10198-021-01414-w




WP4: The role of social costs in economic evaluations of health care decisions in Europe


  • Aranda-Reneo I, Peña-Longobardo LM, Rodríguez-Sánchez B, Oliva-Moreno J, López-Bastida J. How relevant are social costs in economic evaluations? The case of Alzheimer’s disease, Jornadas de Economía de la Salud, 2019 [ PDF]
  • Peña-Longobardo LM, Rodríguez-Sánchez B, Oliva-Moreno J, Aranda-Reneo I, López-Bastida J. (2019). How relevant are social costs in economic evaluations? The case of Alzheimer’s disease. The European Journal of Health Economics, 20(8), 1207–1236. [ https://doi.org/10.1007/s10198-019-01087-6]
  • López-Bastida J, Aranda-Reneo I, Peña-Longobardo LM, Rodríguez-Sánchez B, Oliva-Moreno J. How relevant are social costs in economic evaluations? The case of Rare Diseases – ISPOR 2019 [ Poster PDF]
  • Juliane Andrea Duevel, Lena Hasemann, Luz Maria Peña-Longobardo, Beatriz Rodríguez-Sánchez, Isaac Aranda-Reneo, Juan Oliva-Moreno, Julio López-Bastida, Wolfgang Greiner (2020). Considering the societal perspective in economic evaluations: a systematic review in the case of depression. Health Economics Review, 2020,10 (1):32 [ https://doi.org/10.1186/s13561-020-00288-7]
  • López-Bastida J, Rodríguez-Sánchez B, Aranda-Reneo I, Oliva-Moreno J. Assessing the effect of including social costs in economic evaluations: A systematic review of diabetes-related interventions – ISPOR 2020 [ Poster PDF]
  • López-Bastida J, Düvel AJ, Hasemann L, Peña-Longobardo L.M, Rodríguez-Sánchez B, Aranda-Reneo I, Oliva-Moreno J, Greiner W. Considering the societal perspective in economic evaluations: a systematic review in the case of depression – ISPOR 2020 [ Poster PDF]
  • López-Bastida J, Cichetti A, Rodríguez-Sánchez B, Daugberg S, Peña-Longobardo L.M, Aranda-Reneo I, Oliva-Moreno J. Social costs in multiple sclerosis economic evaluations: do their inclusion change the results and conclusions? A systematic review – ISPOR 2020 [ Poster PDF]
  • Aranda-Reneo I, Rodríguez-Sánchez B, Peña-Longobardo LM, Oliva-Moreno J, López-Bastida J. Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis. Value Health. 2021 Mar;24(3):431-442. doi: 10.1016/j.jval.2020.10.014. Epub 2020 Dec 5. PMID: 33641778. [ Read on PubMed]
  • Rodriguez-Sanchez B, Aranda-Reneo I, Oliva-Moreno J, Lopez-Bastida J. Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review. Clinicoecon Outcomes Res. 2021 Apr 29;13:307–334. [ https://doi.org/10.2147/ceor.s301589]




WP5: Exploring health preferences on different subpopulation groups using EQ-5D





WP6: Methodological guidance on the analysis and interpretation of non-randomised studies to inform health economic evaluatio


  • Kent S, Salcher-Konrad M, Boccia S, Bouvy JC, De Waure C, Espin J, Facey K, Nguyen M, Rejon-Parrilla JC, Jonsson P (2021). The use of nonrandomized evidence to estimate treatment effects in health technology assessment. Journal of Comparative Effectiveness Research https://doi.org/10.2217/cer-2021-0108




WP7: Methodological tools using multi-criteria value methods for HTA decision-making


  • Oliveira MD, et al. (2019). Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. The European Journal of Health Economics 20(6): 891–918. [https://link.springer.com/article/10.1007%2Fs10198-019-01052-3] 10.1007/s10198-019-01052-3




WP8: Analysis of economic evaluation methods for hospital-based assessment


  • Carini E, Gabutti I, Frisicale EM, Di Pilla A, Pezzullo AM, De Waure C, Cicchetti A, Boccia S, Specchia ML (2020) Assessing hospital performance indicators. What dimensions? Evidence from an umbrella review. BMC Health Services Research. [https://doi.org/10.1186/s12913-020-05879-y]
  • Grossi A, Hoxhaj I, Gabutti I, Specchia ML, Cicchetti A, Boccia S, De Waure C (2021) Hospital contextual factors affecting the implementation of health technologies: a systematic review. BMC Health Services Research. [https://doi.org/10.1186/s12913-021-06423-2]
  • Gabutti I (2021). Driving health technologies towards performance: a contextualisation within the hospital setting. International Journal of Technology, Policy and Management. [https://doi.org/10.1504/IJTPM.2021.10043140]




WP9: Expanding economic analysis for HTA: methods for measuring fiscal impact of new healthcare intervention





WP10: Appraisal of Orphan Medicinal Products (OMPs)


  • Facey KM, Rannanheimo P, Batchelor L, Borchardt M, de Cock J (2020). Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU – actions for stakeholders. International Journal of Technology Assessment in Health Care 1–10 [https://doi.org/10.1017/S026646232000063X]
  • Nicod E, Whittal A, Drummond M et al. Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches. Orphanet J Rare Dis 15, 189 (2020) [https://doi.org/10.1186/s13023-020-01462-0]
  • Whittal A, Nicod E, Drummond M, Facey K. Examining the impact of different country processes for appraising rare disease treatments: a case study analysis. International Journal of Technology Assessment in Healthcare. 2021 (in press) [https://pubmed.ncbi.nlm.nih.gov/34044899]
  • Meregaglia M, Whittal A, Nicod E, Drummond M. 'Mapping' health state utility values from non-preference-based measures: a systematic literature review in rare diseases. Pharmacoeconomics. 2020 Jun;38(6):557-574. [https://pubmed.ncbi.nlm.nih.gov/32152892]
  • Meregaglia M, Nicod E, Drummond M. The estimation of health state utility values in rare diseases: overview of existing techniques. Int J Technol Assess Health Care. 2020 Oct;36(5):469-473 [https://pubmed.ncbi.nlm.nih.gov/32981547]
  • Whittal A, Meregaglia M, Nicod E. The use of patient-reported outcome measures in rare diseases and implications for health technology assessment. The Patient. 2021 Jan (open access, in press) [https://link.springer.com/article/10.1007/s40271-020-00493-w]
  • Facey K, Espin J, Kent E et al. Implementing outcomes-based managed entry agreements for rare disease treatments: Nusinersen and Tisagenlecleucel. PharmcoEconomics. July 2021. [https://link.springer.com/article/10.1007/s40273-021-01050-5]
  • Nicod E, Meregaglia M, Whittal A, Upadhyaya S, Facey K, Drummond M (2021) Consideration of quality of life in the health technology assessments of rare disease treatments. European Journal of Health Economics. [https://doi.org/10.1007/s10198-021-01387-w]




WP11: From HTA results to guidance implementation: paving the way


  • Budget impact analysis of triple therapy after failure of methotrexate for the treatment of rheumatoid arthritis in France – ISPOR Europe [weblink]
  • Annual cost of patients undergoing a total knee replacement in France – ISPOR Europe [weblink]